The early diagnosis of preeclampsia is very important, since it is a high risk obstetric pathology. Some biomarkers of angiogenesis in pregnancy that play an important role in placental development to identify diseases that warn of possible levels Preeclampsia.
Preeclampsia: What It Is
Preeclampsia is a medical complication of pregnancy that typically associated three components:- Pregnancy-induced hypertension- Loss of protein in the urine (proteinuria)- EdemaIt can affect up to 10% of pregnancies and is usually a complication of second and third quarters.
Preeclampsia, high-risk obstetric pathology
Currently, and as stated by experts in gynecology and obstetrics , preeclampsia is included within what is called "ischemic placental disease," which includes two other high-risk obstetric pathologies: intrauterine growth retardation and placental abruption.Given the severity and high risk of these diseases, diagnostic strategies are being designed to enable early identification to establish corrective measures to reduce the rate of obstetric risk.
Diagnosis of preeclampsia
Recently they have been discovered biomarkers of angiogenesis in pregnancy that play an important role in the development of placental ischemic disease. They include sFlt-1 and PlGF.- SFlt-1 (soluble fms-like tirosnia kinase-1) is a protein that inactivates factors that cause vascular growth. This protein increases its concentration in the final stage of pregnancy. In pregnant women who develop preeclampsia levels of this protein are increased.- PIGF (Placental Growth Factor) is a key molecule in angiogenesis and its main source during pregnancy is the placenta. Its levels are increased during first and second quarters and decrease at the end.In a patient with preeclampsia levels of sFlt-1 are higher and the PlGF lower than in normal pregnancy.It is approved for clinical use automated methods to value ratio sFlt-1 / PlGF. Using the valuation of this ratio has been proposed to monitor patients at risk of preeclampsia from the 24th week of pregnancy. Sets a risk of developing the disease and the controls that must be subjected to the patients classified as low, intermediate or high risk.